Background: Colorectal mucinous adenocarcinoma (MC) has been associated with impaired prognosis compared with nonmucinous adenocarcinoma (NMC). Response to palliative chemotherapy is poor in metastatic disease, but the benefit of adjuvant chemotherapeutic treatment has never been assessed in large patient groups. This study analyses overall survival and efficacy of adjuvant chemotherapy in terms of survival in patients following radical resection for MC.
introduction
Colorectal cancer (CRC) is the third most common cancer and the fourth most frequent cause of cancer-related mortality worldwide [1, 2] . The majority of cases presents with adenocarcinoma not otherwise specified [3] , but in ∼10%-15% mucinous carcinoma (MC) is reported [4, 5] . At histological examination, MC is composed of more than 50% extracellular mucin [3] . MC more often affects younger patients [6, 7] , is more frequently seen in the proximal colon [6, 8] and in females [6] and usually has a more advanced stage at presentation [7] [8] [9] [10] . The prognostic significance of MC, however, is considered controversial. Most studies demonstrated that patients with MC have a poorer prognosis compared with those with a nonmucinous histology (NMC), which is contradicted by others [4, 6, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Especially, rectal
MCs have been associated with impaired overall survival (OS) [6, 7] . A recent systematic review found a small, but significantly shorter survival in MC versus NMC [hazard ratio (HR) 1.05; 95% confidence interval (CI) 1.02-1.08] [16] .
Fluorouracil-based adjuvant chemotherapy has been demonstrated to be beneficial in stage III colon cancer [15, 20, 21] . Due to the increased stage of presentation of MC, many patients with MC have an indication for adjuvant therapy [11, 22, 23] . However, several studies demonstrated reduced responsiveness of metastatic MC to chemotherapy in the palliative setting, subsequently leading to a worse OS [14, [23] [24] [25] . Due to relative resistance to systemic treatment, therapeutic benefit may be reduced in patients with MC. In the adjuvant setting, the only study taking tumor type into account suggests an equal benefit for MC [10] .
The aim of this study is to establish the role of MC in OS for CRC patients and to identify whether tumor type should be taken into account in decision-making concerning adjuvant chemotherapy following radical resection.
patients and methods
A database containing 27 251 CRC patients diagnosed between 1990 and 2010, was extracted from the population-based Eindhoven Cancer Registry (ECR). Clinicopathological data were recorded by the registration clerks from the hospital records as routine registration for the ECR. Data on follow-up of vital status were retrieved by linkage to the nationwide population registries network. Patients without a histological confirmation of the primary tumor (N = 566) were excluded from this study (Consort diagram in supplementary Figure S1 , available at Annals of Oncology online). Patients were also excluded if they had a previous malignancy within five years preceding the diagnosis of CRC (except for basal cell skin cancer or in situ carcinomas) (N = 1275). Tumors demonstrating a mixed histological picture or undifferentiated carcinoma (N = 112), and tumors that were classified as signet-ring cell carcinoma or other than adenocarcinoma (N = 805) were excluded. Appendiceal carcinomas were also excluded from the study (N = 173). Information about hereditary syndromes was not available in the database.
The following variables were available for this study: age, sex, year of diagnosis, primary tumor location and histology (based upon WHO ICD-O classification), stage at presentation according to the TNM classification (version dependent on year of diagnosis), surgery carried out, (neo)adjuvant therapy, socioeconomic status (SES), co-morbidity and survival time or time from diagnosis until 31 December 2011. To compare adjuvant chemotherapy in stage III, we excluded patients who died within 30 days after surgery for these analyses (N = 145). As grade assignment is largely subjective with few or no defined criteria, and is considered inappropriate for mucinous tumors, this variable was not taken into account [26] . Co-morbidity at diagnosis was registered according to a modified version of the Charlson co-morbidity index, which included among other cardiovascular disease, pulmonary disease or diabetes mellitus. Tumors were classified as proximal if they were found in the cecum, ascending colon or transverse colon up to the splenic flexure and were classified as distal if they were found in the descending or sigmoid colon. SES was defined by the ECR upon postal code, combining mean household income and mean value of the residence. Postal codes were divided into three SES subcategories: low, 
MC as a prognostic factor
In the rectum, there was a significant difference in OS between MC and NMC (5-year OS 41.0% versus 51.2%, P < 0.001) Stage III colon cancer patients showed higher survival in both MC and NMC groups when treated with chemotherapy ( Figure 2A and B) . Median OS in all patients treated with chemotherapy was 133 months, compared with 33 months for patients who were not treated (on univariate analysis P < 0.0001). The multivariate Cox proportional hazard model showed that MC was not an independent prognostic factor in the stage III subgroup when treated with adjuvant chemotherapy (Table 3) .
discussion
MC is a distinct CRC, with different clinical characteristics and prognosis compared with NMC. Due to reduced responsiveness to chemotherapy, MC has a poor prognosis in advanced disease. We showed that colon cancer patients with MC seem to benefit from adjuvant chemotherapy equally to patients with NMC. In the present study over 24 000 prospectively registered CRC patients were analyzed. Approximately 12% of our population consisted of MC, which was constant over time and is consistent with previous reports [4, 10, 13, 14] . Many well-recognized MCassociated features were confirmed in the present study [5-8, 10, 16, 24] .
We found a statistically significant difference in OS between MC and NMC in stage I and III rectal cancer patients, consistent with the current literature [16] . In contrast to previous reports, we could not demonstrate a difference in survival in stage IV [14, 23, 24] . Many studies described a variable prognostic impact of MC [4, 6, 7, 10, 12, [16] [17] [18] 24] . Unfortunately, these studies are generally relatively small and prospectively recorded information often does not include adjuvant treatment details. Furthermore, follow-up time usually is too short to reveal differences between groups adequately, leading to a possible statistical type II error. Moreover, most of the studies were hospital-based and not population-based, which could have led to a selection bias. Even though we are confident that the current study depicts an accurate image of ) . Also, frequencies were comparable with data available in the literature. Secondly, because this populationbased registry does not include information regarding the duration of adjuvant treatment or treatment drugs given during adjuvant chemotherapy, we were not able to account for differences in therapy during the study period. However, when we compared survival in 5-year time periods, we found improved survival following adjuvant chemotherapy to be significant over time (data not shown).
In the present, large population-based study, no differences in OS were demonstrated on multivariate analysis between MC and NMC, except when the tumor was located in the rectum. Consistent with these findings, a recent National Cancer Data Base (USA) study [6] showed that MC of the rectum, but not of the colon is associated with an increased risk of death. Reasons for this difference in OS are not clear, but a possible explanation might be the poorer response to radiotherapy in MCs [11, 22, 27, 28] . Other reasons could be the fact that MCs in the rectum are usually larger, more often have a positive circumferential margin after resection [22] and might therefore have a worse outcome [12] . Further studies are needed to evaluate these factors in rectal cancer.
The efficacy of chemotherapy in MC has mainly been studied in patients receiving palliative chemotherapeutic treatment [14, [23] [24] [25] . In this setting, response is poorer in MC patients compared with NMC patients. The current study confirms that adjuvant chemotherapy for stage III carcinoma is associated with an improved OS. Although patients were not randomized and several biases cannot be accounted for, this finding is consistent with previous randomized trials regarding all CRC patients and current international treatment guidelines [15, 20, 21] . To our knowledge, this is the largest analysis in MC patients concerning adjuvant chemotherapy to date. Interestingly, the present analysis demonstrated a similar survival for NMC and MC patients who underwent adjuvant chemotherapeutic treatment of stage III colon cancer. A recent retrospective analysis [10] with 178 MC patients also suggested a comparable benefit from adjuvant chemotherapy for both stage II and III MCs and NMCs after radical resection. Thus, MC seems clearly responsive to adjuvant chemotherapy and therefore results found in palliative treatment should not be extrapolated to the adjuvant setting.
The mechanisms behind the differences in response to chemotherapy in the adjuvant and palliative setting remain unclear. In general, MC patients have a larger number of metastatic sites and larger primary tumors [23, 29] , with possibly a poorer vasculature, consequently leading to a decreased delivery of therapy. In advanced disease, MC patients also more often suffer from extrahepatic localizations of metastases [14, 23, 24] , such as distant lymph node metastases [12, 24] or peritoneal metastases [12, 24, 25, 29, 30] , which is associated with a poor outcome in CRC [31, 32] .
Based on its histological appearance and its clinicopathological features, MC may be considered a distinct entity with a predominant right-sided location. In consistency with recent literature, we have shown that MC seems to have no impact on survival, except when located in the rectum. Despite lower response to palliative chemotherapy in MC, colon cancer patients treated with adjuvant chemotherapy seem to have similar benefits. Therefore, current adjuvant treatment recommendations should be adhered to regardless of tumor type.
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